$EVMN (EVOMMUNE) — 8-K: EVO756 Phase 2b misses primary endpoint in atopic dermatitis; EVO301 advances

Evommune’s Phase 2b trial of oral MRGPRX2 antagonist EVO756 in 121 adults with moderate-to-severe atopic dermatitis did not meet the primary endpoint of percent change in EASI score from baseline at Week 12, nor any secondary endpoints at any dose studied. EVO756 was generally well tolerated with a safety profile consistent with prior studies. The company does not plan to advance EVO756 in atopic dermatitis but will continue Phase 2b development in migraine prophylaxis. EVO301, an IL-18BP fusion protein with positive Phase 2a proof-of-concept data, becomes the lead atopic dermatitis program with a Phase 2b trial planned for mid-2027.

Evommune’s Phase 2b trial of oral MRGPRX2 antagonist EVO756 in 121 adults with moderate-to-severe atopic dermatitis did not meet the primary endpoint of percent change in EASI score from baseline at W